Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study.

IF 2 4区医学 Q3 ONCOLOGY

Oncology-New York Pub Date : 2026-03-16 DOI:10.46883/2026.25921066

Shiny Chih-Hsuan Wu, Yao-Yu Wu, Chi-Ting Liau, Chih-Hsiang Chang, Shih-Chiang Huang, Hsin-Nung Shih, Chun-Chieh Chen

{"title":"Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study.","authors":"Shiny Chih-Hsuan Wu, Yao-Yu Wu, Chi-Ting Liau, Chih-Hsiang Chang, Shih-Chiang Huang, Hsin-Nung Shih, Chun-Chieh Chen","doi":"10.46883/2026.25921066","DOIUrl":null,"url":null,"abstract":"Background: Soft tissue sarcomas (STS) are rare but aggressive tumors. Although surgery and radiotherapy are standard treatments for localized STS, the role of adjuvant chemotherapy, particularly doxorubicin, in high-grade STS is debated.Methods: This retrospective study evaluated the effectiveness of single-agent doxorubicin in resectable grade 2 and 3 STS, with a focus on oncologic outcomes. Adults with biopsy-confirmed STS of the extremities or trunk, treated at a tertiary center in Taiwan between January 2004 and March 2020, were included. Primary outcomes were distant metastasis-free survival (DMFS) and overall survival (OS).Results: The study enrolled 62 patients in either the single-agent doxorubicin adjuvant chemotherapy group (n = 8) or the observation-only group (n = 54). The mean age was 45.4 years in the adjuvant chemotherapy group and 58.2 years in the observation-only group. The 3-year OS was 100% in the chemotherapy group and 60% in the observation group (log-rank P = .064). The 3-year DMFS rate was 75% in the chemotherapy group and 45% in the observation group (log-rank P = .078).Conclusion: In resectable, high-grade STS of 8 cm or more, single-agent doxorubicin as adjuvant chemotherapy showed a trend toward improved OS and DMFS compared with observation alone; however, statistical significance was not reached.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 2","pages":"106-114"},"PeriodicalIF":2.0000,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology-New York","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.46883/2026.25921066","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Soft tissue sarcomas (STS) are rare but aggressive tumors. Although surgery and radiotherapy are standard treatments for localized STS, the role of adjuvant chemotherapy, particularly doxorubicin, in high-grade STS is debated.

Methods: This retrospective study evaluated the effectiveness of single-agent doxorubicin in resectable grade 2 and 3 STS, with a focus on oncologic outcomes. Adults with biopsy-confirmed STS of the extremities or trunk, treated at a tertiary center in Taiwan between January 2004 and March 2020, were included. Primary outcomes were distant metastasis-free survival (DMFS) and overall survival (OS).

Results: The study enrolled 62 patients in either the single-agent doxorubicin adjuvant chemotherapy group (n = 8) or the observation-only group (n = 54). The mean age was 45.4 years in the adjuvant chemotherapy group and 58.2 years in the observation-only group. The 3-year OS was 100% in the chemotherapy group and 60% in the observation group (log-rank P = .064). The 3-year DMFS rate was 75% in the chemotherapy group and 45% in the observation group (log-rank P = .078).

Conclusion: In resectable, high-grade STS of 8 cm or more, single-agent doxorubicin as adjuvant chemotherapy showed a trend toward improved OS and DMFS compared with observation alone; however, statistical significance was not reached.

查看原文本刊更多论文

单药阿霉素辅助化疗治疗可切除的2/3级软组织肉瘤：回顾性研究

背景：软组织肉瘤是一种罕见的侵袭性肿瘤。虽然手术和放疗是局部STS的标准治疗方法，但辅助化疗，特别是阿霉素在高级STS中的作用仍存在争议。方法：本回顾性研究评估了单药阿霉素在可切除的2级和3级STS中的有效性，重点是肿瘤预后。纳入了2004年1月至2020年3月期间在台湾三级医疗中心接受活检证实的四肢或躯干STS成人患者。主要结局是远端无转移生存期（DMFS）和总生存期（OS）。结果：本研究共纳入62例患者，分别为单药阿霉素辅助化疗组（n = 8）和单纯观察组（n = 54）。辅助化疗组的平均年龄为45.4岁，单纯观察组的平均年龄为58.2岁。化疗组3年OS为100%，观察组为60% （log-rank P = 0.064）。化疗组3年DMFS率为75%，观察组为45% （log-rank P = 0.078）。结论：在可切除的8cm及以上的高度STS中，单药阿霉素辅助化疗与单独观察相比，有改善OS和DMFS的趋势；然而，没有达到统计学意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology-New York 肿瘤学-肿瘤学

CiteScore

1.60

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.